Cargando…
A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII
BACKGROUND: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation provides an opportunity...
Autores principales: | Trembath, Dimitri G, Lal, Anita, Kroll, David J, Oberlies, Nicholas H, Riggins, Gregory J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855066/ https://www.ncbi.nlm.nih.gov/pubmed/17437646 http://dx.doi.org/10.1186/1476-4598-6-30 |
Ejemplares similares
-
Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020) -
The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005) -
Targeting FHL2 for EGFRvIII-positive glioblastoma
por: Sun, Lili, et al.
Publicado: (2018) -
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)